...
aktx-img

Akari Therapeutics PLC, Common Stock

AKTX

NAQ

$1.3

+$0.01

(0.78%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$30.35M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
52.23K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.95
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.9 L
$4.4 H
$1.3

About Akari Therapeutics PLC, Common Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameAKTXSectorS&P500
1-Week Return16.07%-0.09%0.83%
1-Month Return-46.49%0.03%5.98%
3-Month Return-64.48%-6.26%9.65%
6-Month Return-32.64%1.16%14.29%
1-Year Return-59.88%11.16%32.26%
3-Year Return-95.7%11.98%31.61%
5-Year Return-96.67%47.19%94.03%
10-Year Return-99.88%109.06%191.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue19.20K8.91K4.13K3.71K4.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.38,"profit":true},{"date":"2021-12-31","value":21.48,"profit":true},{"date":"2022-12-31","value":19.31,"profit":true},{"date":"2023-12-31","value":20.83,"profit":true}]
Gross Profit(19.20K)(8.91K)(4.13K)(3.71K)(4.00K)[{"date":"2019-12-31","value":-1920500,"profit":false},{"date":"2020-12-31","value":-890700,"profit":false},{"date":"2021-12-31","value":-412600,"profit":false},{"date":"2022-12-31","value":-370800,"profit":false},{"date":"2023-12-31","value":-400000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses24.89M20.10M17.21M23.89M16.81M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":80.77,"profit":true},{"date":"2021-12-31","value":69.16,"profit":true},{"date":"2022-12-31","value":95.99,"profit":true},{"date":"2023-12-31","value":67.52,"profit":true}]
Operating Income(24.87M)(17.98M)(17.21M)(23.09M)(16.81M)[{"date":"2019-12-31","value":-2487000000,"profit":false},{"date":"2020-12-31","value":-1798097400,"profit":false},{"date":"2021-12-31","value":-1721413600,"profit":false},{"date":"2022-12-31","value":-2308820800,"profit":false},{"date":"2023-12-31","value":-1680600000,"profit":false}]
Total Non-Operating Income/Expense122.53K912.97K(199.50K)5.39M-[{"date":"2019-12-31","value":2.28,"profit":true},{"date":"2020-12-31","value":16.95,"profit":true},{"date":"2021-12-31","value":-3.7,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(24.75M)(20.45M)(17.42M)(17.75M)(10.01M)[{"date":"2019-12-31","value":-2475300000,"profit":false},{"date":"2020-12-31","value":-2045400000,"profit":false},{"date":"2021-12-31","value":-1742423700,"profit":false},{"date":"2022-12-31","value":-1774806200,"profit":false},{"date":"2023-12-31","value":-1000800000,"profit":false}]
Income Taxes(2.99M)(2.86M)182.62K(10.78M)-[{"date":"2019-12-31","value":-1636.74,"profit":false},{"date":"2020-12-31","value":-1564.46,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5900.71,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(21.76M)(17.60M)(17.61M)(6.97M)-[{"date":"2019-12-31","value":-2176400000,"profit":false},{"date":"2020-12-31","value":-1759700000,"profit":false},{"date":"2021-12-31","value":-1760685600,"profit":false},{"date":"2022-12-31","value":-697225200,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(17.11M)(17.08M)(17.42M)(17.75M)-[{"date":"2019-12-31","value":-1710579100,"profit":false},{"date":"2020-12-31","value":-1708161700,"profit":false},{"date":"2021-12-31","value":-1742423700,"profit":false},{"date":"2022-12-31","value":-1774806200,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(21.76M)(17.60M)(17.61M)(6.97M)(10.01M)[{"date":"2019-12-31","value":-2176400000,"profit":false},{"date":"2020-12-31","value":-1759700000,"profit":false},{"date":"2021-12-31","value":-1760685600,"profit":false},{"date":"2022-12-31","value":-697225200,"profit":false},{"date":"2023-12-31","value":-1000800000,"profit":false}]
EPS (Diluted)(0.93)--(0.90)-[{"date":"2019-12-31","value":-93,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-89.56,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AKTX
Cash Ratio 0.24
Current Ratio 0.29

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AKTX
ROA (LTM) -172.83%
ROE (LTM) -1281.43%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AKTX
Debt Ratio Lower is generally better. Negative is bad. 3.45
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.45

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AKTX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.07
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Akari Therapeutics PLC share price today?

Akari Therapeutics PLC (AKTX) share price today is $1.3

Can Indians buy Akari Therapeutics PLC shares?

Yes, Indians can buy shares of Akari Therapeutics PLC (AKTX) on Vested. To buy Akari Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Akari Therapeutics PLC be purchased?

Yes, you can purchase fractional shares of Akari Therapeutics PLC (AKTX) via the Vested app. You can start investing in Akari Therapeutics PLC (AKTX) with a minimum investment of $1.

How to invest in Akari Therapeutics PLC shares from India?

You can invest in shares of Akari Therapeutics PLC (AKTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in AKTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Akari Therapeutics PLC shares
What is Akari Therapeutics PLC 52-week high and low stock price?

The 52-week high price of Akari Therapeutics PLC (AKTX) is $4.4. The 52-week low price of Akari Therapeutics PLC (AKTX) is $0.9.

What is Akari Therapeutics PLC price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Akari Therapeutics PLC (AKTX) is

What is Akari Therapeutics PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Akari Therapeutics PLC (AKTX) is 3.07

What is Akari Therapeutics PLC dividend yield?

The dividend yield of Akari Therapeutics PLC (AKTX) is 0.00%

What is the Market Cap of Akari Therapeutics PLC?

The market capitalization of Akari Therapeutics PLC (AKTX) is $30.35M

What is Akari Therapeutics PLC’s stock symbol?

The stock symbol (or ticker) of Akari Therapeutics PLC is AKTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top